Natco witnessed YoY de-growth of 11% in sales in Q1FY20 due to poor sales in the US and decline in Hep-C revenue in India. EBITDA was down by 16% (YoY) while the margin down by 270bps on account of lower realisation in the US . Launched first time generics - apixaban and rivaroxaban in India (June) which are globally mega blockbuster molecules. Key drivers of revenue in FY20 will be India, Brazil and Canada which together is expected to see encouraging growth in FY20-21E....